HC Wainwright set a $24.00 target price on Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a research report released on Tuesday, MarketBeat.com reports. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently weighed in on VRX. Vetr raised Valeant Pharmaceuticals Intl from a strong sell rating to a sell rating and set a $12.46 price objective for the company in a research note on Monday, September 18th. Deutsche Bank reaffirmed a hold rating and issued a $19.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Monday, September 25th. Cantor Fitzgerald reaffirmed a buy rating and issued a $23.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, September 28th. Wells Fargo & Co reaffirmed an underperform rating and issued a $8.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Saturday, September 30th. Finally, ValuEngine upgraded Valeant Pharmaceuticals Intl from a hold rating to a buy rating in a report on Monday, October 2nd. Six research analysts have rated the stock with a sell rating, nine have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals Intl presently has a consensus rating of Hold and a consensus target price of $18.56.

Valeant Pharmaceuticals Intl (NYSE:VRX) traded down $0.60 during midday trading on Tuesday, reaching $22.10. The company had a trading volume of 12,930,900 shares, compared to its average volume of 14,455,017. Valeant Pharmaceuticals Intl has a 12-month low of $8.31 and a 12-month high of $24.43. The stock has a market cap of $7,500.00, a P/E ratio of 5.67, a P/E/G ratio of 0.69 and a beta of -0.22. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a return on equity of 51.56% and a net margin of 15.35%. equities research analysts anticipate that Valeant Pharmaceuticals Intl will post 3.82 earnings per share for the current year.

In related news, Director John Paulson bought 344,216 shares of the stock in a transaction on Thursday, November 16th. The shares were purchased at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the acquisition, the director now owns 94,559 shares in the company, valued at $1,361,649.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.87% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of VRX. Eaton Vance Management boosted its holdings in shares of Valeant Pharmaceuticals Intl by 1.2% during the second quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 500 shares during the last quarter. Stephens Inc. AR acquired a new stake in shares of Valeant Pharmaceuticals Intl during the second quarter worth $299,000. TIAA CREF Investment Management LLC boosted its holdings in shares of Valeant Pharmaceuticals Intl by 36.8% during the second quarter. TIAA CREF Investment Management LLC now owns 609,290 shares of the specialty pharmaceutical company’s stock worth $10,575,000 after purchasing an additional 164,053 shares during the last quarter. Nationwide Fund Advisors boosted its holdings in shares of Valeant Pharmaceuticals Intl by 1.7% during the second quarter. Nationwide Fund Advisors now owns 52,400 shares of the specialty pharmaceutical company’s stock worth $907,000 after purchasing an additional 900 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in shares of Valeant Pharmaceuticals Intl by 10.5% during the second quarter. GSA Capital Partners LLP now owns 21,651 shares of the specialty pharmaceutical company’s stock worth $375,000 after purchasing an additional 2,051 shares during the last quarter. Institutional investors and hedge funds own 49.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals Intl (VRX) PT Set at $24.00 by HC Wainwright” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/01/19/valeant-pharmaceuticals-intl-vrx-pt-set-at-24-00-by-hc-wainwright.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.